Melissa Soliz

speaker

262 appearances 1 recordings 1 series first heard Jun 2026 last heard 23 Jun

Melissa Soliz’s voice in public audio — every appearance, attributed to the second.

Trend

recordings per month · last 12 months

Recordings per month over the last 12 months — 1 in all, peaking in Jun 2026 with 1.

Appearances

newest first · ▶ plays the moment

AHLA's Speaking of Health Law · Latest Developments in Interoperability Litigation · 23 Jun 2026 podcast

And that is gonna be one of the major things that we are going to return to again and again today as we talk about this, is that information blocking might not always be the claim.

But it's increasingly part of the factual and legal vocabulary underlying all the lawsuits we're gonna be talking about.

The second big case we'll be talking about is particle health versus epic.

Particle alleges Epic used its market position and control over access pathways to restrict particles' ability to compete.

Particularly around payer facing data products.

Now the motion to dismiss that we talked about last time um really narrowed the case, but important claims survived.

And since then

As I think Brendan will talk about a bit more, the court has been trying to get clarity around the asserted payer platform market and what do the products actually do.

And this case matters a lot because it tests how far antitrust can go in a world where health data access, systems of records, network participation, and competitive strategy all overlap.

The third case is Cure Is versus Epic.

Cure is is a managed care middleware case.

It alleges that Epic used its position in EHR and payer administration systems to restrict data access, to interfere with customer relationships, and to steer customers towards Epic's own products.

This case may be underappreciated because it's not only about patient access or treatment exchange, it's about the managed care operational layer and whether interoperability friction can become an exclusionary strategy.

Fourth is fine dental, the Henry Shine one or HS one.

This is one of the most interesting recent developments because the preliminary injunction posture kind of separates read access from write access.

Um, as Brendan will talk about a little bit more, the court signaled relief that I think protects certain read pathways while also

restricting functionality capable of writing back to the dendrix databases.

This distinction matters a lot.

It's not just access good or access bad.

It's access for what, through what method, and what risk to system integrity.

Showing 81–100 of 262 · page 5 of 14